{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:49:55Z","timestamp":1772894995922,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,6,25]],"date-time":"2008-06-25T00:00:00Z","timestamp":1214352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s00277-008-0512-x","type":"journal-article","created":{"date-parts":[[2008,6,24]],"date-time":"2008-06-24T13:56:42Z","timestamp":1214315802000},"page":"741-749","source":"Crossref","is-referenced-by-count":34,"title":["Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases"],"prefix":"10.1007","volume":"87","author":[{"given":"Inmaculada","family":"Rapado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enriqueta","family":"Albizua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Angel","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Garcia-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florinda","family":"Gilsanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,25]]},"reference":[{"key":"512_CR1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"512_CR2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148","journal-title":"Nature"},{"issue":"17","key":"512_CR3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u20131790, doi: 10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"issue":"4","key":"512_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397, doi: 10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"issue":"24","key":"512_CR5","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280(24):22788\u201322792, doi: 10.1074\/jbc.C500138200","journal-title":"J Biol Chem"},{"issue":"4","key":"512_CR6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092\u20131097","journal-title":"Blood"},{"issue":"4","key":"512_CR7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood 106(4):1207\u20131209, doi: 10.1182\/blood-2005-03-1183","journal-title":"Blood"},{"issue":"1","key":"512_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","volume":"109","author":"X Xu","year":"2007","unstructured":"Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB et al (2007) JAK2V617F: Prevalence in a large Chinese hospital population. Blood 109(1):339\u2013342","journal-title":"Blood"},{"issue":"9","key":"512_CR9","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","volume":"20","author":"P Sidon","year":"2006","unstructured":"Sidon P, El Housni H, Dessars B, Heimann P (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20(9):1622, doi: 10.1038\/sj.leu.2404292","journal-title":"Leukemia"},{"issue":"10","key":"512_CR10","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","volume":"107","author":"RL Levine","year":"2006","unstructured":"Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107(10):4139\u20134141, doi: 10.1182\/blood-2005-09-3900","journal-title":"Blood"},{"issue":"4","key":"512_CR11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/hon.800","volume":"24","author":"J Poodt","year":"2006","unstructured":"Poodt J, Fijnheer R, Walsh I, Hermans M (2006) A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 24(4):227\u2013233","journal-title":"Hematol Oncol"},{"issue":"7","key":"512_CR12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1373\/clinchem.2006.066886","volume":"52","author":"P Sidon","year":"2006","unstructured":"Sidon P, Heimann P, Lambert F, Dessars B, Robin V, El Housni H (2006) Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. Clin Chem 52(7):1436\u20131438, doi: 10.1373\/clinchem.2006.066886","journal-title":"Clin Chem"},{"key":"512_CR13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162\u20132168","journal-title":"Blood"},{"issue":"7","key":"512_CR14","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292\u20132302, doi: 10.1182\/blood-2002-04-1199","journal-title":"Blood"},{"issue":"10","key":"512_CR15","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood-2003-03-0919","volume":"102","author":"S Klippel","year":"2003","unstructured":"Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U et al (2003) Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 102(10):3569\u20133574, doi: 10.1182\/blood-2003-03-0919","journal-title":"Blood"},{"issue":"3","key":"512_CR16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","volume":"109","author":"N Kroger","year":"2007","unstructured":"Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M et al (2007) Monitoring of V617F-JAK2-mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109(3):1316\u20131321","journal-title":"Blood"},{"issue":"1","key":"512_CR17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","volume":"20","author":"R McClure","year":"2006","unstructured":"McClure R, Mai M, Lasho T (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 20(1):168\u2013171, doi: 10.1038\/sj.leu.2404007","journal-title":"Leukemia"},{"issue":"4","key":"512_CR18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1309\/TK0XL917XK2VLRPQ","volume":"125","author":"G Murugesan","year":"2006","unstructured":"Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR et al (2006) Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 125(4):625\u2013633, doi: 10.1309\/TK0X-L917-XK2V-LRPQ","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"512_CR19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.5858\/2006-130-997-DOTJMI","volume":"130","author":"RJ Olsen","year":"2006","unstructured":"Olsen RJ, Tang Z, Farkas DH, Bernard DW, Zu Y, Chang CC (2006) Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 130(7):997\u20131003","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"512_CR20","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","volume":"109","author":"J Kittur","year":"2007","unstructured":"Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanksyj AP et al (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109(11):2279\u20132284","journal-title":"Cancer"},{"issue":"9","key":"512_CR21","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 21(9):1952\u20131959, doi: 10.1038\/sj.leu.2404854","journal-title":"Leukemia"},{"issue":"1","key":"512_CR22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/asheducation-2006.1.240","volume":"2006","author":"A Tefferi","year":"2006","unstructured":"Tefferi A (2006) Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F Era. Hematology 2006(1):240\u2013245, doi: 10.1182\/asheducation-2006.1.240","journal-title":"Hematology"},{"issue":"10","key":"512_CR23","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","volume":"106","author":"RL Levine","year":"2005","unstructured":"Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E et al (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106(10):3377\u20133379","journal-title":"Blood"},{"issue":"8","key":"512_CR24","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","volume":"106","author":"PS Goerttler","year":"2005","unstructured":"Goerttler PS, Steimle C, Marz E, Johansson PL, Andreasson B, Griesshammer M et al (2005) The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 106(8):2862\u20132864","journal-title":"Blood"},{"issue":"10","key":"512_CR25","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","volume":"106","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Teo S-S, Buser AS, Brutsche M, Tiedt R, Tichelli A et al (2005) Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 106(10):3374\u20133376","journal-title":"Blood"},{"issue":"2","key":"512_CR26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li C-Y, Dingli D et al (2005) Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 131(2):166\u2013171","journal-title":"Br J Haematol"},{"issue":"10","key":"512_CR27","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","volume":"19","author":"E Antonioli","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19(10):1847\u20131849, doi: 10.1038\/sj.leu.2403902","journal-title":"Leukemia"},{"issue":"5","key":"512_CR28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2141.2005.05951.x","volume":"132","author":"AM Vannucchi","year":"2006","unstructured":"Vannucchi AM, Guglielmelli P, Antonioli E, Mappa S, Pancrazzi A, Bogani C et al (2006) Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. Br J Haematol 132(5):652\u2013654","journal-title":"Br J Haematol"},{"issue":"5","key":"512_CR29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.2005.05950.x","volume":"132","author":"A Tefferi","year":"2006","unstructured":"Tefferi A (2006) Inconsistencies in the association between JAKV617F mutation and PRV-1 over-expression among the chronic myeloproliferative disorders\u2014response to Vannucchi et al. Br J Haematol 132(5):654\u2013654","journal-title":"Br J Haematol"},{"issue":"2","key":"512_CR30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131(2):208\u2013213, doi: 10.1111\/j.1365-2141.2005.05764.x","journal-title":"Br J Haematol"},{"issue":"9501","key":"512_CR31","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945\u20131953, doi: 10.1016\/S0140-6736(05)","journal-title":"Lancet"},{"issue":"3","key":"512_CR32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","volume":"77","author":"PG Heller","year":"2006","unstructured":"Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD et al (2006) JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 77(3):210\u2013216","journal-title":"Eur J Haematol"},{"issue":"1","key":"512_CR33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","volume":"93","author":"E Antonioli","year":"2008","unstructured":"Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G et al (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93(1):41\u201348, doi: 10.3324\/haematol.11653","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0512-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0512-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0512-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T15:26:54Z","timestamp":1631460414000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0512-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,25]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0512-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,25]]}}}